Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Collaborative Groups / Breast and Gynecologic Cancers Research Group / FDA approved autoantibody panel identified as potential serum biomarker for triple-negative breast cancer

FDA approved autoantibody panel identified as potential serum biomarker for triple-negative breast cancer

OVA1 for Ovarian Cancer

Click here to visit the biomarker database for more information on OVA1.

EDRN Orientation Meeting 2016
The In-person EDRN Orientation Meeting will take place Wednesday, October 19-Friday, October 21, 2016 in Bethesda, MD. More information such as meeting registration and hotel reservations can be found here.
Announcement